Gene therapy a new approach in dentistry: human or microbial gene modification
AbstractIntroduction: This review provides an update on transfer techniques and clinical implications of gene therapy in dentistry. Gene therapy is a new biomedicine emerging field that manipulates genes to achieve gain function in patient cells. Gene therapy essentially consists of introducing specific genetic material into target cells to compensate for abnormal genes or to make a beneficial protein without producing toxic effects on surrounding tissue. Gene therapy can be used to treat wide range of diseases ranging from single gene disorder to multi gene disorder. It has variety of applications in the field of dentistry like in periodontal disease, cancerous and precancerous condition, salivary gland disorders, autoimmune diseases, bonerepair, DNA vaccination, etc. Minor salivary glands and keratinocytes present in the oral mucosa are excellent target sites for gene therapy since it can be readily accomplished with minimal invasive manner. As a new aspect scientists investigating for tooth regrown using shark gene networkactivation in human cells. Applications of gene therapy to dental and oral problems illustrate the potential impact of this technology on dentistry. Aim of this article is to description in brief on the application, limitation and disadvantage of gene therapy in dentistry.Key words: Gene therapy, Dentistry, Viral vector, Stem cell.
Hijjawi J, Mogford JE, Chandler LA, Cross KJ, Said H, Sosnowski BA, et al. Platelet-derived growth factor B, but not fibroblast growth factor 2, plas- mid DNA improves survival of ischemic mucocu- taneous flaps. Arch Surg. 2004;139:142–7.
Dunn CA, Jin QM, Taba M, Jr, Franceshi RT, Bruce Rutherford R, Giannobile WV.BMP gene deliveryfor alveolar bone engineering at dental implant defects.MolTher. 2005;11:294–9.
Jeremy Mao, 2010.http://www.popsci.com/science/article/2010-05/new technique uses bodys stem cells regenerate teeth.
BaumB J, KokM, TranS D, YamanoS. The impact of gene therapy on dentistry: A revisiting after six years. J Am Dent Assoc. 2002;133(1):35-44.
Anusaksathien O, Jin Q, Zhao M, Somerman MJ, Giannobile WV. Effect of sustained gene delivery of platelet-derived growth factor or its antagonist (PDGF-1308) on tissue-engineered cementum.J Periodontol. 2004;75:429–40.
Franceschi RT, Wang D, Krebsbach PH, Rutherford RB. Gene therapy for bone formation: In vitro and in vivo osteogenic activity of an adenovirus ex- pressing BMP-7. J Cell Biochem. 000;78:476–86.
Hijjawi J, Mogford JE, Chandler LA, Cross KJ, Said H, Sosnowski BA, et al. Platelet-derived growth factor B, but not fibroblast growthfactor 2, plas- mid DNA improves survival of ischemic mucocu- taneous flaps. Arch Surg. 2004;139:142–7.
Anusaksathien O, Webb SA, Jin QM, Giannobile WV. Platelet- derived growth factor gene deliv- ery stimulates ex vivo gingival repair. Tissue Eng.2003;9:745–56.
Printz MA, Gonzalez AM, Cunningham M, Gu DL, Ong M, Pierce GF, et al. Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxici- ty relative to native adenoviral vectors. Hum Gene Ther. 2000;11:191–204.
Huang GT, Zhang HB, Kim D, Liu L, Ganz T. A model for antimicrobial gene therapy: Demon- stration of human betadefensin 2 antimicrobial activities in vivo. Hum Gene Ther. 2002;13:2017–25.
Sharma A, Honma K, Evans RT, Hruby DE, Genco RJ.Oral immunization with recombinant Strepto- coccus gordonii expressing porphyromonasgingi- valisFimA domains. Infect Immun. 2001;69:2928–34.
Jin QM, Anusaksathien O, Webb SA, Rutherford `RB, Giannobile WV. Engineering of tooth- sup-porting structures by delivery of PDGF gene ther-apy vectors. MolTher. 2004;9:519.
Kaiger D, Cirelli JA, Giannobile WV. Growth fac or delivery for oral and periodontal tissue engi- neering. Expert Opin Drug Deliv. 2006;3:647–62.
Karthikeyan VB, Pradeep RA. Gene therapy in periodontics. A review and future implications. The J contemporary Dental practice 2006: 7(3):83-91.
Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, O’Toole GA. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance.Nature.2003;426:306–10.
Tsuchiya S, Chiba M, Kishimoto K, Nakamura H, Mitani H. Tohoku University, Sendai. Gene trans- fer into periodontal tissue by in vivo electropora- tion. [2011 Sep 01].
Katz J, Black KP, Michalek SM. Host responses to recombinant hemagglutinin B of Porphyromonas gingivalis in an experimental rat model. Infect Im- mun. 1999;67:4352–9.
Schreiner HC, Sinatra K, Kaplan JB, Furgang D, Kachlany SC, Planet PJ, et al. Tight-adherence genes of required for virulence in rat model. Proc Natl AcadSci U S A. 2003; 100:7295–300.
Seo BM, Miura M, Gronthos S, Bartold PM, Bato- uli S, Brahim J, et al. Investigation of multipotent postnatal stem cells from human periodontal liga- ment. Lancet. 2004; 364:149–55.
Zhu Z, Lee CS, Tejeda KM, Giannobile WV. Gene transfer and expression of platelet-derived growth factors modulate periodontal cellular activity. J Dent Res. 2001;80:892–7.
A signature of author below certifies compliance with the following statements:
Copyright transfer; in signing this Agreement:
1. I hereby warrant that this article is an original work, has not been published before and is not being considered for publication elsewhere in its final form either in printed or electronic form;
2. I hereby warrant that you have obtained permission from the copyright holder to reproduce in the Article (in all media including print and electronic form) material not owned by you, and that you have acknowledged the source;
3. I hereby warrant that this article contains no violation of any existing copyright, moral rights or other third party right or any material of an obscene, indecent, defamatory or otherwise unlawful nature and that to the best of your knowledge this Article does not infringe the rights of others;
4. I hereby warrant that in the case of a multi-authored Article you have obtained, in writing, authorization to enter into this Agreement on their behalf and that all co-authors have read and agreed the terms of this agreement;
5. I warrant that any formula or dosage given is accurate and will not if properly followed injure any person;
6. I have made a significant scientific contribution to the study and I have read the complete manuscript and take responsibility for the content and completeness of the final surmised manuscript;
7. I will indemnify and keep indemnified the Editors, the Journal's Editor against all claims and expenses (including legal costs and expenses) arising from any breach of this warranty and the other warranties on your behalf in this Agreement.
Conflict of interest disclosure
All institutional or corporeal affixations of mine and all funding sources for the study are acknowledged. I certify that I have no commercial association that might represent a conflict of interest in connection with the submitted manuscript.